{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:18:40Z","timestamp":1791908320957,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Governo Italiano Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004770","name":"University of Parma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A17196"],"award-info":[{"award-number":["A17196"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A23982"],"award-info":[{"award-number":["A23982"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["A31287"],"award-info":[{"award-number":["A31287"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CUP D53D23007840001"],"award-info":[{"award-number":["CUP D53D23007840001"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["2022C5RHRT"],"award-info":[{"award-number":["2022C5RHRT"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003887","name":"International Myeloma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003887","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bneo.2026.100195","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:06:28Z","timestamp":1768388788000},"page":"100195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A metabolic trade-off between malignant plasma cells and mesenchymal stromal cells sustains multiple myeloma growth"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9606-1171","authenticated-orcid":false,"given":"Giuseppe","family":"Taurino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-2547","authenticated-orcid":false,"given":"Erika","family":"Griffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Toscani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8544","authenticated-orcid":false,"given":"Chiara","family":"Maccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Tardito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano G.","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Casati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2810-1263","authenticated-orcid":false,"given":"Erica","family":"Dander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1761-460X","authenticated-orcid":false,"given":"Roberta","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3457-3774","authenticated-orcid":false,"given":"Nicola","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Bussolati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-9984","authenticated-orcid":false,"given":"Martina","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bneo.2026.100195_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bneo.2026.100195_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","article-title":"Glutamine addiction: a new therapeutic target in cancer","volume":"35","author":"Wise","year":"2010","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.bneo.2026.100195_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/med.21511","article-title":"Metabolism within the tumor microenvironment and its implication on cancer progression: an ongoing therapeutic target","volume":"39","author":"Ocana","year":"2019","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bneo.2026.100195_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ceb.2017.05.006","article-title":"Metabolism shapes the tumor microenvironment","volume":"48","author":"Reina-Campos","year":"2017","journal-title":"Curr Opin Cell Biol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100195_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bneo.2026.100195_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.bneo.2026.100195_bib7","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies","volume":"117","author":"Korde","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100195_bib8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: a major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bneo.2026.100195_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216171","article-title":"Single-cell RNA sequencing reveals XBP1-SLC38A2 axis as a metabolic regulator in cytotoxic T lymphocytes in multiple myeloma","volume":"562","author":"Wan","year":"2023","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.bneo.2026.100195_bib10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-01-690743","article-title":"Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target","volume":"128","author":"Bolzoni","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2026.100195_bib11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3390\/ijms19041099","article-title":"Oligodendroglioma cells lack glutamine synthetase and are auxotrophic for glutamine, but do not depend on glutamine anaplerosis for growth","volume":"19","author":"Chiu","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bneo.2026.100195_bib12","doi-asserted-by":"crossref","first-page":"10250","DOI":"10.1038\/s41598-020-67105-3","article-title":"Metabolomic and lipidomic profiling of bone marrow plasma differentiates patients with monoclonal gammopathy of undetermined significance from multiple myeloma","volume":"10","author":"Gonsalves","year":"2020","journal-title":"Sci Rep"},{"issue":"17","key":"10.1016\/j.bneo.2026.100195_bib13","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-12-2917","article-title":"Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission","volume":"19","author":"Puchades-Carrasco","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.bneo.2026.100195_bib14","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1038\/s41375-025-02715-2","article-title":"High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease","volume":"39","author":"Toscani","year":"2025","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bneo.2026.100195_bib15","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.3390\/cancers12113267","article-title":"Myeloma cells deplete bone marrow glutamine and inhibit osteoblast differentiation limiting asparagine availability","volume":"12","author":"Chiu","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bneo.2026.100195_bib16","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.cmet.2019.01.016","article-title":"Glutamine metabolism regulates proliferation and lineage allocation in skeletal stem cells","volume":"29","author":"Yu","year":"2019","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.bneo.2026.100195_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2026.100195_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.714755","article-title":"The role of amino acids in the crosstalk between mesenchymal stromal cells and neoplastic cells in the hematopoietic niche","volume":"9","author":"Chiu","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"23","key":"10.1016\/j.bneo.2026.100195_bib19","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1182\/bloodadvances.2020004041","article-title":"ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment","volume":"5","author":"Chiu","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2026.100195_bib20","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/bcj.2012.40","article-title":"Mesenchymal stem cells from Shwachman-Diamond syndrome patients display normal functions and do not contribute to hematological defects","volume":"2","author":"Andre","year":"2012","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.bneo.2026.100195_bib21","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity","volume":"267","author":"O'Brien","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.bneo.2026.100195_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101532","article-title":"Mesenchymal stromal cells cultured in physiological conditions sustain citrate secretion with glutamate anaplerosis","volume":"63","author":"Taurino","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.bneo.2026.100195_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215649","article-title":"System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance","volume":"535","author":"Wang","year":"2022","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.bneo.2026.100195_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40170-020-00235-4","article-title":"In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells","volume":"8","author":"Gonsalves","year":"2020","journal-title":"Cancer Metab"},{"issue":"4","key":"10.1016\/j.bneo.2026.100195_bib25","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","article-title":"Targeting glutamine metabolism as a therapeutic strategy for cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Exp Mol Med"},{"issue":"1","key":"10.1016\/j.bneo.2026.100195_bib26","doi-asserted-by":"crossref","first-page":"e94543","DOI":"10.1172\/jci.insight.94543","article-title":"Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies","volume":"3","author":"Gonsalves","year":"2018","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.bneo.2026.100195_bib27","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s12276-020-00504-8","article-title":"Glutamine reliance in cell metabolism","volume":"52","author":"Yoo","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.bneo.2026.100195_bib28","doi-asserted-by":"crossref","first-page":"e28083","DOI":"10.7554\/eLife.28083","article-title":"Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer","volume":"6","author":"Sayin","year":"2017","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.bneo.2026.100195_bib29","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/ars.2011.4391","article-title":"The cystine\/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities","volume":"18","author":"Lewerenz","year":"2013","journal-title":"Antioxid Redox Signal"},{"issue":"3-4","key":"10.1016\/j.bneo.2026.100195_bib30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s10495-023-01909-2","article-title":"Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis","volume":"29","author":"Zhang","year":"2024","journal-title":"Apoptosis"},{"issue":"5","key":"10.1016\/j.bneo.2026.100195_bib31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41418-022-00943-y","article-title":"p53 in ferroptosis regulation: the new weapon for the old guardian","volume":"29","author":"Liu","year":"2022","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bneo.2026.100195_bib32","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1182\/blood-2005-04-1489","article-title":"Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma","volume":"106","author":"Stuhmer","year":"2005","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bneo.2026.100195_bib33","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1182\/bloodadvances.2020001639","article-title":"Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death","volume":"4","author":"Soncini","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.bneo.2026.100195_bib34","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00018-013-1484-0","article-title":"Changes in the expression of the glutamate transporter EAAT3\/EAAC1 in health and disease","volume":"71","author":"Bianchi","year":"2014","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.bneo.2026.100195_bib35","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ncb2432","article-title":"Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia","volume":"14","author":"Zhang","year":"2012","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100195_bib36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bjh.19516","article-title":"Asparagine transport through SLC1A5\/ASCT2 and SLC38A5\/SNAT5 is essential for BCP-ALL cell survival and a potential therapeutic target","volume":"205","author":"Taurino","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100195_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1039\/D1MO00106J","article-title":"Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma","volume":"18","author":"Zaal","year":"2022","journal-title":"Mol Omics"},{"key":"10.1016\/j.bneo.2026.100195_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2021.02.020","article-title":"Inhibition of the L-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors","volume":"507","author":"Prelowska","year":"2021","journal-title":"Cancer Lett"},{"issue":"22","key":"10.1016\/j.bneo.2026.100195_bib39","doi-asserted-by":"crossref","first-page":"35863","DOI":"10.18632\/oncotarget.16262","article-title":"Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells","volume":"8","author":"Thompson","year":"2017","journal-title":"Oncotarget"},{"issue":"30","key":"10.1016\/j.bneo.2026.100195_bib40","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1038\/onc.2015.464","article-title":"Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax","volume":"35","author":"Bajpai","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.bneo.2026.100195_bib41","article-title":"Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment","volume":"13","author":"Montoya","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.bneo.2026.100195_bib42","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neuroscience.2012.09.055","article-title":"Valproic acid induces the glutamate transporter excitatory amino acid transporter-3 in human oligodendroglioma cells","volume":"227","author":"Bianchi","year":"2012","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.bneo.2026.100195_bib43","doi-asserted-by":"crossref","first-page":"C550","DOI":"10.1152\/ajpcell.00169.2023","article-title":"The SLC38A5\/SNAT5 amino acid transporter: from pathophysiology to pro-cancer roles in the tumor microenvironment","volume":"325","author":"Taurino","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"issue":"18","key":"10.1016\/j.bneo.2026.100195_bib44","doi-asserted-by":"crossref","first-page":"8284","DOI":"10.18632\/oncotarget.2058","article-title":"Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease","volume":"5","author":"Garcia-Gomez","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.bneo.2026.100195_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3057624","article-title":"Mesenchymal stem cell-based immunomodulation: properties and clinical application","volume":"2018","author":"Wang","year":"2018","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.bneo.2026.100195_bib46","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fphys.2013.00275","article-title":"Adipose tissue immunity and cancer","volume":"4","author":"Catalan","year":"2013","journal-title":"Front Physiol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100195_bib47","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bneo.2026.100195_bib48","article-title":"Harnessing the immune system against multiple myeloma: challenges and opportunities","volume":"10","author":"Yamamoto","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100195_bib49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728222.2017.1279148","article-title":"The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma","volume":"21","author":"Giuliani","year":"2017","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"10.1016\/j.bneo.2026.100195_bib50","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3390\/ijms21051899","article-title":"Functional consequences of low activity of transport system A for neutral amino acids in human bone marrow mesenchymal stem cells","volume":"21","author":"Chiu","year":"2020","journal-title":"Int J Mol Sci"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:25:33Z","timestamp":1779294333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950328026000063"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100195","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A metabolic trade-off between malignant plasma cells and mesenchymal stromal cells sustains multiple myeloma growth","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100195"}}